Histone deacetylases, as a new class of anticancer targets, could maintain homeostasis by
catalyzing histone deacetylation and play important roles in regulating the expression of …

There is a wide range of important pharmaceuticals used in treatment of cancer. Besides
their known effects on tumor cells, there is growing evidence for modulation of the immune …

Abstract Hematopoietic progenitor kinase 1 (HPK1) is predominantly expressed in
hematopoietic cells and is a negative regulator of T cell receptor (TCR) signaling. Recent …

Simple Summary It is a long-held notion that loss-of-function mutations in negative
regulators of the Hippo-YAP pathway, such as NF2, LATS1/2, have a similar potential to …

Multidrug resistance (MDR) in cancer arises from cross-resistance to structurally-and
functionally-divergent chemotherapeutic drugs. In particular, MDR is characterized by …

Therapy with Tyrosine Kinase Inhibitors (TKI) aiming stable deep molecular response is the
gold standard to treat Chronic Myeloid Leukemia (CML). NKT-like cells (CD3+ CD56+) …

Abstract B-cell CLL/lymphoma 6 (BCL6) exerts oncogenic effects in several human
hematopoietic malignancies including chronic myeloid leukemia (CML), where BCL6 …

Tyrosine kinase inhibitors have greatly improved the prognosis of chronic myeloid leukemia
(CML). In addition to direct kinase inhibition, their effects can also be mediated through …

Tumors are genetically complex and can have a multitude of mutations. Consequently, it is
surprising that the suppression of a single oncogene can result in rapid and sustained tumor …

Purpose Acute B-lymphoblastic leukemia (B-ALL) is a malignant disease characterized by
accumulation of clonal immature lymphocytes in the bone marrow and peripheral blood. The …